➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Moodys
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca

Last Updated: March 3, 2021

DrugPatentWatch Database Preview

ZEVALIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for ZEVALIN

Identify potential brand extensions & biosimilar entrants

SponsorPhase
National Cancer Institute (NCI)Phase 3
University of California, DavisPhase 2
Duke UniversityPhase 2

See all ZEVALIN clinical trials

Recent Litigation for ZEVALIN

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
GENENTECH, INC. v. CELLTRION, INC.2018-01-11
GENENTECH, INC. v. SANDOZ, INC.2017-12-20

See all ZEVALIN litigation

PTAB Litigation
PetitionerDate
2017-12-20

See all ZEVALIN litigation

Company Disclosures: US Patents for ZEVALIN

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial Idec Pharmaceuticals Corporation (San Diego, CA) 2015-04-07 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceuticals Corporation (San Diego, CA) 2015-07-07 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial 2015-12-01 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceuticals Corporation (San Diego, CA) 2039-03-29 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceutical Corporation (San Diego, CA) 2019-06-04 RX Orphan company
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial IDEC Pharmaceuticals Corporation (San Diego, CA) 2021-01-27 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for ZEVALIN

These patents were identified by searching patent claims

Supplementary Protection Certificates for ZEVALIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
122016000049 Germany   Start Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
CR 2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
300753 Netherlands   Start Trial PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
PA2015031 Lithuania   Start Trial PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
CA 2004 00021 Denmark   Start Trial PRODUCT NAME: IBRITUMOMAB TIUXETAN
122004000036 Germany   Start Trial FORMER OWNER: BIOGEN IDEC INC.(N.D.GES.D.STAATES DELAWARE), SAN DIEGO, CALIF., US
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Harvard Business School
Moodys
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.